- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Merz appoints James P. Hartman vice president, medical dermatology
Merz has announced that James P. Hartman has been appointed vice president, medical dermatology, effective June 12, 2012. Mr. Hartman will be responsible for the company’s medical and OTC/OTX dermatology business unit, which includes Naftin (naftifine hydrochloride) and Mederma.
Greensboro, N.C. - Merz has announced that James P. Hartman has been appointed vice president, medical dermatology, effective June 12, 2012. Mr. Hartman will be responsible for the company's medical and OTC/OTX dermatology business unit, which includes Naftin (naftifine hydrochloride) and Mederma.
"Jim has a proven track record when it comes to developing and commercializing pharmaceutical and OTC/OTX products. We are extremely pleased to have him join the Merz team, and are confident he will make immediate and important contributions to the continued growth of our medical dermatology business and the company as a whole," said Bill Humphries, president and CEO of Merz.
Mr. Humphries noted that additional senior-level hires are anticipated within the next few months as Merz undergoes integration and prepares for accelerated growth across all business units.
Prior to joining Merz, Mr. Hartman was vice president, global marketing and business development, at Obagi Medical Products. Previously, he was senior vice president, U.S. commercial operations, and vice president of U.S. marketing for Stiefel Laboratories. Mr.Hartman also has held senior-level positions with Allergan and SmithKline Beecham (now GlaxoSmithKline).
